The Best Path to C> Commercial Success
The cell and gene therapy (C>) market is maturing and near-term growth is accelerating. There are over a dozen cell and gene therapies already approved in the U.S. and more than 350 additional treatments in development.
Innovation in cell and gene therapy brings new commercial challenges. Each new commercialization of a cell and gene therapy treatment has unique roadblocks as physicians, patients, and payers acclimate to the science of these new cell and gene therapy entrants, as well as their evolving approaches to commercialization and distribution.
In this whitepaper you will discover:
The four most common challenges in cell and gene therapy commercialization.
Methods to address common product launch challenges.
Insights to accelerate and de-risk launch for cell and gene therapy treatments.
Commercialization of cell and gene therapy treatments can provide significant value across advanced therapy medicine products (ATMPs), driven by a combination of their clinical benefit and durability, as well as being able to treat the root cause of disease and provide curative effects.
In such a nascent field, few organizations have the experience to inform the best path to commercial success. Herspiegel Consulting has supported numerous cell and gene therapy (C>) companies with their first commercialization efforts.